Innoviva (INVA) reported Q2 EPS of $0.05, which may not compare to the analyst estimate of $0.44. Revenue for the quarter came in at $111.7 million versus the consensus estimate of...
Pre-Open Stock Movers:La Jolla Pharmaceutical Co (NASDAQ:LJPC) 81% HIGHER; Innoviva Inc (NASDAQ:INVA), a diversified holding company with a portfolio of royalties and a growing...
With coronavirus on the verge of becoming a global pandemic, investors went into overdrive scurrying for safe-haven assets to counter the uncertainty. This, in turn, sent gold...
We expect royalties from Innoviva, Inc.’s (NASDAQ:INVA) collaborated drugs to have driven revenues in fourth-quarter 2019.Shares of the company have lost 12.4% in the past...
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced that it has enrolled the first patient in the pivotal phase II/III study evaluating its novel asparaginase JZP-458 as a potential...
Innoviva, Inc. is a company with a portfolio of royalties and other healthcare assets. The Company's royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/ vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI) and TRELEGY ELLIPTA (the combination FF/UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA and royalties from the sales of ANORO ELLIPTA. RELVAR/BREO ELLIPTA is a once-daily combination medicine consisting of a LABA, vilanterol (VI), and an inhaled corticosteroid (ICS), fluticasone furoate (FF). ANORO ELLIPTA is a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with an LABA, VI. TRELEGY ELLIPTA (the combination FF/UMEC/VI), a once-daily combination medicine consisting of an ICS, LAMA, and LABA.